Seroatlas · Human Serome Atlas

CLDN9

Claudin-9

Also known as: CLD9_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O95484
Gene: CLDN9
Ensembl: ENSG00000213937
Chromosome: 16
Canonical length: 217 aa
Protein class: Disease related genes, Human disease related genes, Predicted membrane proteins
Subcellular location: Vesicles,Cell Junctions

OverviewNCBI Gene

This gene encodes a member of the claudin family. Claudins are integral membrane proteins and components of tight junction strands. Tight junction strands serve as a physical barrier to prevent solutes and water from passing freely through the paracellular space between epithelial or endothelial cell sheets, and also play critical roles in maintaining cell polarity and signal transductions. This protein is one of the entry cofactors for hepatitis C virus. Mouse studies revealed that this gene is required for the preservation of sensory cells in the hearing organ and the gene deficiency is associated with deafness. [provided by RefSeq, Jun 2010]

Canonical amino-acid sequenceUniProt

217 residues, UniProt reviewed canonical sequence.

>O95484|CLDN9
     1  MASTGLELLG MTLAVLGWLG TLVSCALPLW KVTAFIGNSI VVAQVVWEGL WMSCVVQSTG
    61  QMQCKVYDSL LALPQDLQAA RALCVIALLL ALLGLLVAIT GAQCTTCVED EGAKARIVLT
   121  AGVILLLAGI LVLIPVCWTA HAIIQDFYNP LVAEALKREL GASLYLGWAA AALLMLGGGL
   181  LCCTCPPPQV ERPRGPRLGY SIPSRSGASG LDKRDYV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CLDN9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 4
Mean surface accessibility (rSASA): 0.36
Highest tissue expression: 29 nTPM

Expression across tissuesHPA

Tissue

pituitary gland: 29 nTPM
cerebellum: 27 nTPM
pancreas: 7 nTPM
liver: 5.7 nTPM
spinal cord: 4.6 nTPM
basal ganglia: 4.1 nTPM

Single-cell type

corticotrophs: 39 nCPM
pancreatic duct cells: 31 nCPM
cholangiocytes: 18 nCPM
epididymal efferent duct ciliated cells: 16 nCPM
epididymal basal cells: 14 nCPM
respiratory ciliated cells: 12 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebellum: 18 nTPM
pons: 7 nTPM
cerebral cortex: 6.6 nTPM
medulla oblongata: 5.9 nTPM
white matter: 5.9 nTPM
basal ganglia: 4.6 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about CLDN9.

Disease | AllUniProt

Conditions CLDN9 is implicated in, by any mechanism.

Deafness, autosomal recessive, 116 (DFNB116) MIM:619093

Disease | GeneticClinVar

3 pathogenic / likely-pathogenic of 72 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Hearing loss, autosomal recessive 116
Hearing loss

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.9
gnomAD pLI: 0
gnomAD missense Z: -1.08
DepMap mean gene effect: -0.05
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of CLDN9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CLDN9 as an antibody target. Whether an autoantibody or antibody against CLDN9 could matter depends on whether native CLDN9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CLDN9 is annotated at the cell surface, where native CLDN9 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CLDN9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...